作者
Talal El Zarif,Karl Semaan,Wanling Xie,Marc Eid,Martín Zarbá,Wadih Issa,Tian Zhang,Charles B. Nguyen,Ajjai Alva,Catherine C. Fahey,Kathryn E. Beckermann,José A. Karam,Matthew T. Campbell,Giuseppe Procopio,Marco Stellato,Sebastiano Buti,Anežka Zemánková,Bohuslav Melichar,Francesco Massari,Veronica Mollica,Balaji Venugopal,Hedyeh Ebrahimi,Guillermo de Velasco,Howard Gurney,Ugo De Giorgi,Omi Parikh,Eric Winquist,Viraj A. Master,Abraham Ruiz Garcia,Hernan Javier Cutuli,Thomas Ferguson,Marine Gross‐Goupil,Sylvan C. Baca,Sumanta K. Pal,David A. Braun,Rana R. McKay,Daniel Yick Chin Heng,Toni K. Choueiri
摘要
Adjuvant pembrolizumab significantly improved overall survival (OS) in renal cell carcinoma (RCC), but real-world data on sequential treatment are scarce. We sought to evaluate the clinical outcomes of first-line (1L) systemic therapy following adjuvant immune oncology (IO)-based regimens.
毛豆
爱静静
丰知然
嘉心糖
iNk
yar
小鱼爱吃肉
36456657
子车茗
fillippo99
pcr163
sissiarno
蒋时晏
林荫下的熊
大气的鹭洋
pluto
杳鸢
tuanheqi
Billy
Ganlou
皖公网安备34019202002308
